A method of fixating carbon dioxide (CO.sub.2) to form a substituted oxazolidinone is described. The method includes mixing a metal-organic framework (MOF), at least one epoxide, and at least one aromatic amine to form a mixture. The method further includes contacting the mixture with a gas stream containing CO.sub.2 to react the CO.sub.2 in the gas stream with the epoxide and the aromatic amine to form a substituted oxazolidinone. The MOF is a MIL-68(In)-X MOF. X is of formula (I):

##STR00001##

where at least one of R.sup.1 to R.sup.4 is an amine-containing group, and R.sup.1 to R.sup.4 are independently an amine-containing group or a hydrogen.

A method of fixating carbon dioxide (CO.sub.2) to form a substituted oxazolidinone is described. The method includes mixing a metal-organic framework (MOF), at least one epoxide, and at least one aromatic amine to form a mixture. The method further includes contacting the mixture with a gas stream containing CO.sub.2 to react the CO.sub.2 in the gas stream with the epoxide and the aromatic amine to form a substituted oxazolidinone. The MOF is a MIL-68(In)-X MOF. X is of formula (I):

##STR00001##

where at least one of R.sup.1 to R.sup.4 is an amine-containing group, and R.sup.1 to R.sup.4 are independently an amine-containing group or a hydrogen.

Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.

Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na.sup.+K.sup.+Cl.sup. co-transporter or GABA.sub.A receptor.

The present invention provides novel synthetic methods for making acyclic secondary amines by reacting an azide with a compound bearing one or more CH groups, catalyzed by a Fe.sup.II-dipyrromethene complex. The acyclic secondary amines are thought to be formed through an intermolecular nitrene transfer. Also provided herein are methods of synthesizing protected (e.g., Boc- or Fmoc-protected) cyclic secondary amines (e.g., 5-, 6-, and 7-membered cyclic secondary amines) by reacting an azide that bears one or more CH groups, catalyzed by a Fe.sup.II-dipyrromethene complex. The protected cyclic secondary amines are thought to be formed through an intramolecular nitrene transfer and may be subsequently deprotected to yield cyclic secondary amines.

The present invention provides novel synthetic methods for making acyclic secondary amines by reacting an azide with a compound bearing one or more CH groups, catalyzed by a Fe.sup.II-dipyrromethene complex. The acyclic secondary amines are thought to be formed through an intermolecular nitrene transfer. Also provided herein are methods of synthesizing protected (e.g., Boc- or Fmoc-protected) cyclic secondary amines (e.g., 5-, 6-, and 7-membered cyclic secondary amines) by reacting an azide that bears one or more CH groups, catalyzed by a Fe.sup.II-dipyrromethene complex. The protected cyclic secondary amines are thought to be formed through an intramolecular nitrene transfer and may be subsequently deprotected to yield cyclic secondary amines.

Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.

Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables R.sup.A, R.sup.AA, subscript n, subscript q, ring A, X.sup.2, L, subscript m, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

##STR00001##